| Biologic Therapy |
1 |
1 |
| CAR-T |
0 |
0.91 |
| Multiple Myeloma |
0 |
0.67 |
| Cancer |
0 |
0.4 |
| Lymphoma |
0 |
0.15 |
| Remission |
0 |
0.15 |
| Non-Hodgkin Lymphoma (NHL) |
0 |
0.14 |
| B-Cell Lymphoma |
0 |
0.13 |
| Blood |
0 |
0.12 |
| Face |
0 |
0.12 |
| Healthcare and Medical Technology |
0 |
0.1 |
| Clinical Research |
0 |
0.09 |
| Leukemia |
0 |
0.09 |
| Chronic Lymphocytic Leukemia |
0 |
0.07 |
| Bone Marrow Transplant |
0 |
0.06 |
| Immunotherapy |
0 |
0.06 |
| Transplant Evaluation |
0 |
0.05 |
| Bone Marrow |
0 |
0.04 |
| Stem Cell Research and Therapy |
0 |
0.04 |
| Antigens |
0 |
0.03 |
| Biomedical Technology |
0 |
0.03 |
| Bone |
0 |
0.03 |
| California |
0 |
0.03 |
| Complementary and Alternative Medicine |
0 |
0.03 |
| Hematologic Malignancies |
0 |
0.03 |
| Hematology |
0 |
0.03 |
| Quality Control (QC) |
0 |
0.03 |
| Receptors |
0 |
0.03 |
| Texas |
0 |
0.03 |
| Transplantation |
0 |
0.03 |